Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Treasury Shares (2023 - 2024)

Corvus Pharmaceuticals has reported Treasury Shares over the past 2 years, most recently at $400000.0 for Q3 2024.

  • Quarterly results put Treasury Shares at $400000.0 for Q3 2024, changed N/A from a year ago — trailing twelve months through Sep 2024 was $400000.0 (changed N/A YoY), and the annual figure for FY2023 was $400000.0, changed.
  • Treasury Shares for Q3 2024 was $400000.0 at Corvus Pharmaceuticals, roughly flat from $400000.0 in the prior quarter.
  • Over the last five years, Treasury Shares for CRVS hit a ceiling of $400000.0 in Q4 2023 and a floor of $400000.0 in Q4 2023.